Tanuk Pharma (India) Limited, a active public limited company, was established on 28 February 1995 in New Delhi, Delhi, India. Engaging in pharmaceutical retailers & distributors within the pharma sector, it holds CIN: U74899DL1995PLC065899. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹8.50 Cr and a paid-up capital of ₹3.67 Cr.
It upholds a compliant status. Its leadership includes Lokesh Kumar Saxena (Additional Director), Pankaj Kumar Thakur (Director), Kidar Nath Bhalla (Director). Past directors included Anuradha Bhalla, Pankaj Kumar Thakur, Pankaj Kumar Jha. It holds ₹1.05 Cr open charges and ₹6.00 Cr settled loans. Its latest AGM occurred on 25 September 2023, with the balance sheet filed on 31 March 2023. It is based at A-11 Kailash Apartments Lala Lajpatrai Marg, New Delhi, Delhi, 110048.
U74899DL1995PLC065899
065899
28 February 1995
₹8.50 Cr
₹3.67 Cr
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Tanuk Pharma (India) Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Lokesh Kumar Saxena | Additional Director | 23 Nov 2023 | Current |
| Pankaj Kumar Thakur | Director | 10 Aug 2016 | Current |
| Kidar Nath Bhalla | Director | 02 Feb 2015 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 28 Nov 2023 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2016 | Past |
| Pramod Abcsdd | Director | 02 Feb 2015 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2015 | Past |
| Pramod Abcsdd | Director | 28 Nov 2023 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Tanuk Pharma (India) Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.91% increase. The company also saw a substantial improvement in profitability, with a 99.62% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Tanuk Pharma (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹10,450,000.00
₹60,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Mar 2015 | Housing Development Finance Corporation Limited | ₹7.00 M | Open |
| 19 Sep 2011 | Standard Chartered Bank | ₹3.45 M | Open |
| 16 May 2014 | Bank Of Baroda | ₹3.25 Cr | Satisfied |
| 10 Feb 1997 | Punjab National Bank | ₹2.75 Cr | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Tanuk Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Tanuk Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tanuk Pharma (India)'s trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Lokesh Kumar Saxena was appointed as a Additional Director was appointed as a Additional Director on 23 Nov 2023 & has been associated with this company since 2 years 8 days . was documented.
Progress on Tanuk Pharma (India) Limited last Annual general meeting of members was held on 25 Sep 2023 as per latest MCA records. was documented.
Progress on Tanuk Pharma (India) Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Delhi. was documented.
Progress on Pankaj Kumar Thakur was appointed as a Director was appointed as a Director on 10 Aug 2016 & has been associated with this company since 9 years 3 months . was documented.
A charge registered on 16 May 2014 via Charge ID 10500350 with Bank Of Baroda was fully satisfied on 22 Jan 2016. was recorded as a recent event.
A charge with Housing Development Finance Corporation Limited amounted to Rs. 0.70 Cr with Charge ID 10560192 was registered on 31 Mar 2015. was recorded as a recent event.
The CIN of Tanuk Pharma (India) Limited is U74899DL1995PLC065899.
Tanuk Pharma (India) Limited is headquartered at A-11 Kailash Apartments Lala Lajpatrai Marg, New Delhi, Delhi, 110048.
Tanuk Pharma (India) Limited was incorporated on 28 February 1995.
The current directors of Tanuk Pharma (India) Limited are
The primary industry of Tanuk Pharma (India) Limited is Pharma.
Tanuk Pharma (India) Limited is unlisted.
The authorized capital of Tanuk Pharma (India) Limited is ₹8.50 Cr, and the paid-up capital is ₹3.67 Cr.
The compliance status of Tanuk Pharma (India) Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX